Skin manifestations of diabetes

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 11, 2008, Pages 772-787

  Van Hattem, Simone ^a,b   Bootsma, Aart T ^b   Thio, H Bing ^b  

^a AMPHIA HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

CHEMICALLY INDUCED DISORDER; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SKIN DISEASE;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RISK FACTORS; SKIN DISEASES;

EID: 58149459446     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.11.772     Document Type: Review

References (56)

1. Landau J, Davis E. The small blood-vessels of the conjunctiva and nail bed in diabetes mellitus. Lancet 1960; 2:731
2. Huntley A. Diabetes mellitus: review. Dermatology Online Journal 1995; vol 1(2). http://dermatology.cdlib.org/DOJvol1num2/diabetes/ dmreview.html. Accessed July 30, 2008.
3. Ahmed I, Goldstein B. Diabetes mellitus. Clin Dermatol 2006; 24:237-246.
4. Petzelbauer P, Wolff K, Tappeiner G. Necrobiosis lipoidica: treatment with systemic corticoids. Br J Dermatol 1992; 126:542.
5. Sibbald RG, Schachter RK. The skin and diabetes mellitus. Int J Dermatol 1984; 23:567-584.
6. Ferringer T, Miller F. Cutaneous manifestations of diabetes mellitus. Dermatol clin 2002; 20:483-492.
7. Cohen O, Yaniv R, Karasik A, Trau H. Necrobiosis lipoidica and diabetic control revisited. Med Hypotheses 1996; 45:348-350.
8. Nguyen K, Washenik K, Shupak J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 2002; 46(suppl 2):34-36.
9. Stanway A, Rademaker M, Newman P. Healing of severe ulcerative necrobiosis lipoidica with cyclosporine. Australas J Dermatol 2004; 45:119-122.
10. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003; 88:2983-2992.
11. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy-evidence-based analysis of the literature. J Dtsch Dermatol Ges 2007; 5:467-475.
12. Petrou-Amerikanou C, Markopoulos AK, Belazi M, Karamitsos D, Papanayotou P. Prevalence of oral lichen planus in diabetes mellitus according to the type of diabetes. Oral Dis 1998; 4:37-40.
13. Mobini N, Toussaint S, Kamino H. Noninfectious, erythematous, papular, and squamous diseases. In: Elder DE, editor. Lever's Histopathology of the Skin. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:179-214.
14. Nikoleishvill LR, Kurashvili RB, Virsaladze DK. Characteristic changes of skin and its accessories in type 2 diabetes mellitus. Georgian Med News 2006; 131:43-46.
15. Lithner F, Hietala S-O. Skeletal lesions of the feet in diabetics and their relationship to cutaneous erythema with or without necrosis of the feet. Acta Med Scand 1976; 200:155-161.
16. Collier A, Matthews DM, Kellett HA, Clarke BF, Hunter JA. Change in skin thickness associated with cheiroarthropathy in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1986; 292:936.
17. Perez MI, Kohn SR. Cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1994; 30:519-530.
18. Libecco JF. Finger pebbles and diabetes: a case with broad involvement of the dorsal fingers and hands. Arch Dermatol 2001; 137:510-511.
19. Brik R, Berant M, Vardi P. The scleroderma-like syndrome of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1991; 7:121-128.
20. Jelinek JE. Cutaneous manifestations of diabetes mellitus. Int J Dermatol 1994; 33:605-617.
21. Huntley AC. The cutaneous manifestations of diabetes mellitus. J Am Acad Dermatol 1989; 7:427-455.
22. Jennings AM, Milner PC, Ward JD. Hand abnormalities are associated with the complications of diabetes in type 2 diabetes. Diabet Med 1989; 6:43-47.
23. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 1983; 6:189-192.
24. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol 1987; 67:175-177.
25. Margolis J, Margolis LS. Skin tags - a frequent sign of diabetes mellitus [letter]. N Engl J Med 1976; 294:1184.
26. Garcia Hidalgo L. Dermatological complications of obesity. Am J Clin Dermatol 2002; 3:497-506.
27. Scheinfeld NS. Obesity and dermatology. Clin Dermatol 2004; 22:303-309.
28. Crook MA. Skin tags and the atherogenic lipid profile. J Clin Pathol 2000; 53:873-874.
29. Tompkins RR. Skin tags and diabetes. Arch Dermatol 1977; 113:1463.
30. Sibbald RG, Landolt SJ, Toth D. Skin and diabetes. Endocrinol Metab Clin North Am 1996; 25:463-472.
31. Hermanns-Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am J Clin Dermatol 2004; 5:199-203.
32. Katz RA. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol 1980; 116:110.
33. Morton CA, Henderson IS, Jones MC, Lowe JG. Acquired perforating dermatosis in a British dialysis population. Br J Dermatol 1996; 135:671-677.
34. Saray Y, Seçkin D, Bilezikçi B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006; 20:679-688.
35. Wilmer WA, Magro CM. Calciphylaxis:emerging concepts in prevention. diagnosis, and treatment. Dialysis 2002; 15:172-186.
36. Muller SA. Dermatologic disorders associated with diabetes mellitus. Mayo Clin Proc 1966; 41:689.
37. Meurer M, Stumvoll M, Szeimies RM. Hautveränderungen bei Diabetes mellitus. Hautartz 2004; 55:428-435.
38. Grammer L. Insulin allergy. Clin Rev Allergy 1986; 4:189-200.
39. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4:661-667.
40. Murao S, Hirata K, Ishida T, Takahara J. Lipoatrophy induced by recombinant human insulin injection. Intern Med 1998; 37:1031-1033.
41. Barranco R, Herrero T, Tornero P, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58:536-537.
42. Burge MR, Carey JD. Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes. Diabetes Care 2004; 27:275-276.
43. Durand-Gonzalez KN, Guillausseau N, Pecquet C, Gayno JP. Glargine insulin is not an alternative in insulin allergy. Diabetes Care 2003; 26:2216.
44. Blumer IR. Severe injection site reaction to insulin detemir. Diabetes Care 2006; 29:946.
45. Darmon P, Castera V, Koeppel MC, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care 2005; 28:2980.
46. Deerochanawong C, Chandrapraset S. Glimepiride in type 2 diabetes mellitus Thai patients. J Med Assoc Thai 2001; 84:1221-1228.
47. Noakes R. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride. Australas J Dermatol 2003; 44:302-303.
48. Koca R, Altinyazar HC, Yenidünya S, Tekin NS. Psoriasiform [sic] drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J 2003; 9:11. http://dermatology.cdlib.org/93/ case_reports/metformin/koca.html. Accessed July 30, 2008.
49. Burger DE, Goyal S. Erythema multiforme from metformin. Ann Pharmacother 2004; 38:1537.
50. Klapholz L, Leitersdorf E, Weinrauch L. Leucocytoclastic vasculitis and pneumonitis induced by metformin: BMJ (Clin Res Ed) 1986; 293:483.
51. Ben Salem C, Hmouda H, Slim R, Denguezli M, Belajouza C, Bouraoui K. Rare case of metformin-induced leucocytoclastic vasculitis. Ann Pharmacother 2006; 40:1685-1687.
52. Litt JZ. Litt's Drug Eruption Reference Manual. London: Taylor and Francis, 2001.
53. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46:1024-1054. Erratum in: Drugs 1994; 48:929.
54. Kono T, Hayami M, Kobayashi H, Ishii M, Taniguchi S. Acarbose-induced generalized erythema multiforme. Lancet 1999; 354:396-397.
55. 14C acarbose to rats, dogs and man. Arzneimittelforschung 1989; 39:1254-1260.
56. Poszepczynska-Guigné E, Viguier M, Assier H, Pinquier L, Hochedez P, Dubertret L. Acute generalized exanthematous pustulosis induced by drugs with low-digestive absorption: acarbose and nystatin. Ann Dermatol Venereol 2003; 130:439-442.